Long-term efficacy of immune checkpoint inhibitors for relapsed primary mediastinal B-cell lymphoma: a real-world studyBeatrice Casadei, Pier Luigi Zinzani, Lisa Argnani et al.|Blood Advances|2025Cited by 2
Further strategies after immune checkpoint inhibitors in relapsed/refractory Hodgkin lymphoma: salvage treatments and consolidation with transplantation, experience in daily clinical practiceCinzia Pellegrini, Pier Luigi Zinzani, Nicole Fabbri et al.|Annals of Hematology|2025Cited by 2
SARS-CoV-2 infection does not affect the outcome of patients with relapsed/refractory large B-cell lymphoma treated with CAR T-cell therapyMarianna Gentilini, Pier Luigi Zinzani, Beatrice Casadei et al.|Annals of Hematology|2025Cited by 0
348 | LONG‐TERM EFFICACY OF IMMUNE CHECKPOINT INHIBITORS FOR RELAPSED/REFRACTORY PRIMARY MEDIASTINAL B‐CELL LYMPHOMA: A RETROSPECTIVE, MONOCENTRIC STUDY FROM BOLOGNA, ITALYVittorio Stefoni, P. L. Zinzani, Pierluca Maglio et al.|Hematological Oncology|2025Cited by 0